Crossject
Created in 2001
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
1,163 5,372Activities
Technologies
Entity types
Location
6 Rue Pauline Kergomard, 21000 Dijon, France
Dijon
France
Employees
Scale: 51-200
Estimated: 94
Engaged corporates
21
8 4Added in Motherbase
3 years, 4 months ago
deeptech Value proposition
Expert des médicaments d'urgence auto-administrés
Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.
Injection sans aiguile and Traitements d'urgenceOriginal language
Expert des médicaments d'urgence auto-administrés
Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.
Crossject | Needle free injection | ZENEO®
Crossject developed ZENEO®, a world-leading needle-free injection platform, designed to improve patients’ safety and comfort and to enable a better observance of treatments. Needleless free injection of medicinal solution.
https://www.crossject.com/en
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 | Ministère de la Défense | Other 21 Oct 2024 | | |
 J.P. Morgan Bank | J.P. Morgan Bank | Other 10 Jan 2024 | | |
 Eurofins Scientifique Biotechnology, Biotechnology Research | Eurofins Scientifique Biotechnology, Biotechnology Research | Other 23 Jul 2024 | | |
 Business France National and local authorities, Government Administration | Business France National and local authorities, Government Administration | Other 17 May 2024 | | |
 | ANSM Agence nationale de sécurité du médicament et des produits de santé | Other 7 Sep 2023 | | |
 Syneos Health Pharmaceutical, Biotechnology Research | Syneos Health Pharmaceutical, Biotechnology Research | Other 30 Sep 2024 | | |
 | Gouvernement | Other 4 Oct 2023 | | |
 MEDEF NGO, Think Tank, Civic and Social Organizations | MEDEF NGO, Think Tank, Civic and Social Organizations | Other 27 Sep 2023 | | |
 La Tribune Media, Newspapers | La Tribune Media, Newspapers | Other 1 Sep 2023 | | |
 Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Other 13 Mar 2024 | | |